This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Siemens and BioNTech cooperate on production of personalised cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalised cancer immunotherapies, have entered into a strategic collaboration.

BioNTech AG’s subsidiaries, BioNTech RNA Pharmaceuticals GmbH and EUFETS GmbH, will work together with Siemens on the construction of a fully automated and digitalised production site to provide capacity for BioNTech’s truly personalised cancer vaccines to serve worldwide markets. The cooperation will enable BioNTech to establish and integrate all necessary process and production steps for manufacturing its IVAC® individualised vaccines at a larger scale.

This strategic collaboration brings together each partner’s specific competences in order to optimise automation and digitalisation technology for a paperless, commercial-scale GMP (Good Manufacturing Practice) manufacturing of truly personalised medicines.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

Ugur Sahin, CEO of BioNTech, said: “We are pleased to partner with Siemens on automating a specialised, proprietary manufacturing process for truly personalised medicine. Siemens’ world-class expertise in engineering and optimising automatic manufacturing processes will be of great value in making personalised cancer treatment for patients available to all.

Eckard Eberle, CEO of the Siemens Business Unit Process Automation, added: “The development and manufacturing of personalised medicine is connected with massive amounts of data. Solutions such as our manufacturing operations management (MOM) software are able to handle the complexity of this innovative new process technology. Together with BioNTech’s competence in individualised medicine, we will pave the way for a digital plant with an efficient and completely paperless production.

The IVAC® MUTANOME Immunotherapy approach is based on targeting the unique mutation signature of an individual patient’s tumour. It is engineered on demand and administered as an individual treatment. IVAC® MUTANOME is currently in a Phase I/IIa clinical trial for the treatment of malignant melanoma.

Siemens offers a paperless manufacturing solution for enhancing both efficiency and product quality, while at the same time bringing down costs. Fully integrated communication is established between the automation level and manufacturing IT. As a central access point for all process and quality relevant data, the solution links advanced scheduling with the manufacturing execution and the laboratory management system. This enables complete electronic recording and documentation of quality-related production data, while eliminating time-consuming manual procedures and paper-based batch reports. Paperless manufacturing thus accelerates the design, execution, review and release of pharmaceutical production processes and electronic batch records (EBRs).